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Hepatocellular carcinomaAbstract Background: Approximately 80% of patients with hepatocellular carcinoma (HCC) are
untreatable because of advanced tumor stages at presentation. Therefore, ﬁnding newer markers for
screening and diagnosing HCC is of utmost importance. Clusterin (CLU) is a 449 amino acid, hete-
rodimeric glycoprotein with a plausible role in the regeneration, migration, and anti-apoptosis of
tumor cells. It has been implicated in many malignancies such as prostate and pancreatic adenocar-
cinomas, but its role in HCC is not well deﬁned.
Objective: We aimed to evaluate the diagnostic performance of serum CLU level in diagnosing
HCC on top of hepatitis C virus-related liver cirrhosis, and comparing it to that of alpha fetoprotein
(AFP).
Methods: Twenty cases of apparently healthy subjects, 27 cases of hepatitis C virus-related liver
cirrhosis (CHC cases), and 44 HCC cases on top of hepatitis C virus-related liver cirrhosis were
included in this study. Serum CLU concentration was determined using a quantitative sandwich
enzyme immunoassay technique.
Results: Serum clusterin level showed a signiﬁcant increase in the HCC group compared to the
control group (151.96 ± 32.74 vs. 111.40 ± 27.46) and to the CHC group (151.96 ± 32.74 vs.
89.12 ± 31.62), while a signiﬁcant decrease in serum clusterin level was found in the CHC group
compared to the control group (89.12 ± 31.62 vs. 111.40 ± 27.46). Based on receiver operator
228 R.A. Ramadan et al.characteristic curve analysis, serum AFP still surpassed serum CLU in diagnostic sensitivity (77.3%
vs. 70.5%), speciﬁcity (100% vs. 90%), and positive and negative predictive values (100% vs. 86.1%
and 83.3% vs. 77.6% respectively). The use of a combined parallel approach improved the diagnos-
tic sensitivity (95.5%) and negative predictive value (95.7%) over the single use of AFP.
Conclusions: Although the diagnostic performance of serum AFP outperformed that of serum
CLU, their combined parallel approach improved the sensitivity which is required in screening high
risk populations such as CHC patients.
ª 2014 Alexandria University Faculty of Medicine. Production and hosting by Elsevier B.V. All rights
reserved.1. Introduction
Hepatocellular carcinoma (HCC) is the ﬁfth most common
cancer worldwide and the most common form of primary liver
cancer.1 In Egypt, the overall frequency of HCC is 2.3%
among other types of cancer. Over a decade, there was nearly
a twofold increase in the proportion of HCC among chronic
liver disease patients in Egypt, where 48% of HCC cases were
attributed to hepatitis C virus (HCV) related liver cirrhosis. In
fact, it has now become widely accepted that HCC nearly
exclusively arises in chronic HCV after cirrhosis is established.2
HCC is typically diagnosed late in its course. Indeed,
patients who present with cancer symptoms and/or with vascu-
lar invasion or extra-hepatic spread have only 50% survival
rate at one year. Therapeutic options are determined both by
tumor extent and the severity of the underlying liver disease.
Although the cornerstone of therapy is surgical resection, the
majority of patients are not eligible because of tumor extent
or underlying liver dysfunction.
The diagnosis of HCC can be radiological and/or labora-
tory. Radiological diagnosis depends largely on ultrasonogra-
phy, triphasic computerized tomography (triphasic CT-scan)
and dynamic magnetic resonance imaging (dynamic MRI).
The sensitivity of US for the detection of HCC is directly
related to tumor size. Another major drawback of US is that
it is very much operator- dependent.4,5 Laboratory diagnosis
of HCC is established either by measurement of circulating
biomarkers or by ﬁne-needle cytology which is invasive with
intra- or inter-observer variability.6
The American Association for the Study of Liver Diseases
(AASLD) guidelines recommended that serum levels of AFP
P200 ng/ml may be used instead of ﬁne-needle cytology for
diagnosis, especially in patients with liver cirrhosis.3 Neverthe-
less, the diagnostic performance of AFP is moderate with a
sensitivity of 39–65% and speciﬁcity of 76–94%, leaving about
one-third of cases with early-stage HCC and small tumors
(<3 cm) undiagnosed. Meanwhile, increased serum AFP con-
centration in several other types of cancer, chronic hepatitis,
and liver cirrhosis should be taken into consideration. Newer
markers are needed to overcome these problems and allow
the diagnosis of HCC at an earlier stage.1,6
Clusterin (CLU) is a 449-amino acid, heterodimeric glyco-
protein that is ubiquitously expressed and present in most
body ﬂuids. Functionally, CLU exerts a chaperone-like activ-
ity with action like small heat shock proteins, by binding to
misfolded stressed proteins. In contrast to other heat shock
proteins, it is present in the extracellular space, where its
expression is altered in various diseases.7–9So far, CLU is thought to play diverse functions both cyto-
protective and cytotoxic, thus resulting in conﬂicting results.9
For example, its involvement in numerous physiological pro-
cesses important for carcinogenesis has been reported, includ-
ing apoptotic cell death, cell adhesion, tissue remodeling, cell
cycle regulation, DNA repair, lipid transportation, membrane
recycling and immune system regulation.10 Cytoplasmic CLU
immunostaining was noted to correlate with poor prognosis
in patients with renal cell carcinoma,11 hepatocellular carci-
noma,12 urothelial bladder carcinoma,13 and prostate adeno-
carcinoma.14 Also increased expression of secreted CLU was
associated with radioresistance, chemoresistance, and hor-
mone resistance, making CLU a promising target for antitu-
mor therapeutics.15 Both preclinical and clinical phase
studies demonstrated that inhibition of CLU expression using
antisense oligonucleotides enhances the apoptosis induced by
several chemotherapeutic treatments.10 On the other hand,
cytoplasmic CLU staining correlated with good prognosis in
pancreatic adenocarcinoma and did not correlate with progno-
sis in breast carcinoma.16,17
As the data are still sporadic and only few studies have
investigated CLU in serum, the aim of the present study was
to determine serum CLU concentration in CHC and HCC,
as well as assess the use of clusterin measurement vs. AFP in
the diagnosis of HCC.2. Materials and methods
A total of 127 adults at the Medical Research Institute Teach-
ing Hospital, Alexandria University, Egypt between August
2010 and April 2012 were candidates for this study, but only
91 cases fulﬁlled our inclusion and exclusion criteria. All sub-
jects (or their legal guardians) gave their informed consent to
the study, which was approved by the local ethics committee
of the institute in accordance with The Code of Ethics of the
World Medical Association (Declaration of Helsinki) for
experiments involving humans. These subjects were set into
three groups based on clinical and laboratory characteristics:
- Group 1(G1): Healthy subjects. This group included 20
apparently healthy blood donors with no history of liver
disease.
- Group 2 (G2): 27 patients with chronic hepatitis-C virus
infection-related cirrhosis (CHC).
- Group 3 (G3): 44 patients with hepatocellular carcinoma
on top of chronic HCV infection-related cirrhosis (HCC
group).
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mation about health status, current medications, alcohol con-
sumption, and history of viral or toxic hepatitis; had a physical
examination and the Child-Pugh scoring system was used for
staging the severity of liver disease. Conventional ultrasound
and spiral CT-scans of the abdomen were performed in all
cases.
Following an overnight eight-hour-fast, eight milliliters of
whole venous blood samples were withdrawn from each sub-
ject; whole EDTA blood was used for complete blood picture,
citrated plasma for prothrombin time determination, serum
for routine clinical chemistry and AFP assays and ﬁnally the
serum was stored in aliquots at 20 C for the determination
of CLU.
For all studied groups screening for serum schistosomal
IgG antibodies was done using the indirect haemagglutination
test. Serological testing for anti-HCV and hepatitis B virus sur-
face antigen (HBs-Ag) was performed by sandwich enzyme
linked immunosorbent assay (ELISA) technique according to
the manufacturer’s instructions (Murex Diagnostic Limited.
Dartfold, England). HCV viral load was determined by means
of the second generation branched DNA assay (Quantiplex
HCV RNA 2.0; Bayer Diagnostics, Emeryville, California,
USA). Serum AFP concentration was determined using a
two site chemiluminometric immunoassay (ACS–180, Siemens
Healthcare Diagnostics, Germany) by the Immulite 1000
Automated Analyzer (Diagnostic Products Corporation).
Serum CLU concentration was determined using the
ELISA technique according to the manufacturer’s
instructions (Biovendor-Laboratorni Medicina a.s., Cat. No.
RD194034200R). The assay had a lowest detection limit of
0.5 ng/mL. The remaining biochemical parameters were mea-
sured using routine methods by fully automated chemistry
analyzer Olympus AU400. The upper limit of alanine amino-
transferase (ALT) activity was set at 38 IU/L, aspartate
aminotransferase (AST) at 40 IU/L, alkaline phosphatase at
120 IU/L, and gamma glutamyl transferase at 55 and
38 IU/L for males and females respectively. Results of analyses
were validated using internal and external quality control
provided by Biorad USA.
Hepatitis C related cirrhosis patients (CHC) are those who
had (1) positive serum anti-HCV antibodies; (2) cirrhosis com-
patible with HCV origin proved on ultrasound and spiral CT-
scans; and (3) absence of HCC deﬁned by the absence of a
focal liver mass on ultrasonography or CT scan.
The diagnosis of HCC was based on the criteria published
by the Egyptian Society of Liver Cancer (ESLC) in 2011.
These included the presence of a hepatic focal lesion in high
risk patients (cirrhotic patients) plus either serum AFP
P200 ng/ml, or a triphasic CT-scan showing typical criteria
for HCC. If in the presence of a focal lesion P1 cm the AFP
level was <200 ng/ml or triphasic CT-scan of the abdomen
showed a typical criteria for HCC, then either a dynamic con-
trast MRI or targeted liver biopsy was performed.18
‘‘Early stage HCC’’ were identiﬁed according to the Milan
criteria; those who either have one nodule <5 cm, or three
nodules each <3 cm in diameter.19 Meanwhile, vascular inva-
sion, regional lymph node involvement, peritoneal deposits
and/or distant metastases were designated as ‘‘extrahepatic
spread of HCC’’.
Patients were excluded if they had (a) hepatitis B virus
(HBV), human immunodeﬁciency virus (HIV), or schistosomalco-infection, (b) personal history of diabetes or fasting serum
glucose P7.0 mmol/L, or a 2-h postprandial serum glucose
P11.1 mmol/L, (c) history of ischemic heart disease during
the previous 6 months, uncontrolled hypertension, unstable
angina, or severe cardiac arrhythmia,20 (d) alcohol consump-
tion >30 g/day (e) inadequate kidney function (creatinine level
P150 lmol/L), and (f) received concomitant antitumor
treatment.21
2.1. Statistical analysis
Statistical analysis was done using SPSS version 18 (SPSS,
Inc., Chicago, IL, USA). Normality test was done by the Shap-
iro-Wilk W test. Descriptive measures were done for each var-
iable in every group. Data comparison between groups was
done using the Mann–Whitney test. Spearman correlation
coefﬁcient (r) was applied to our results. A p-value less than
0.05 were considered statistically signiﬁcant.
For choosing the best cut off value, receiver operator char-
acteristic (ROC) curve was generated and the Youden’s index
[Youden Index = (sensitivity + speciﬁcity) 1] was calcu-
lated.22The best cut off values had the highest Youden indices.
Diagnostic performance of each marker alone (diagnostic
speciﬁcity, diagnostic sensitivity, positive and negative predic-
tive values) was compared to the surrogate use of both markers
(combined parallel approach) in HCC cases.3. Results
The studied subjects comprised 91 individuals (20 apparently
healthy volunteers: mean age 52.7 ± 3.9 years; 10 (50%) males
and 10 (50%) females, 27 CHC cases: mean age
52.53 ± 4.27 years; 18 (66.7%) males and 9 (33.3%) females,
and ﬁnally HCC cases: mean age 52.18 ± 4.09 years; 25
(56.8%) males and 19 (43.2%) females). According to Child-
Pugh (CP) classes, CHC patients in the present study included
8 cases (29.6%) CP class A, 10 cases (37%) CP class B, and 9
cases (33.3%) CP class C. While HCC patients included 13
cases (29.5%) CP class A, 14 cases (31.8%) CP class B, and
17 cases (38.6%) CP class C. Based on the Milan criteria,
the studied HCC cases can be sorted into early and late stage
HCC; 9 cases (9.9%) and 35 cases (38.5%) respectively. Also
the HCC group included 10 cases (11%) with extrahepatic
spread and 34 cases (37.5%) without extrahepatic spread.
All subjects in the control group had normal liver biochem-
istry. As expected, serum AFP (ng/ml) was signiﬁcantly higher
in the HCC cases compared to both the control group
(7243 ± 11613.6 vs. 2.79 ± 1.26) (p< 0.001), as well as to
CHC patients (7243 ± 11613.6 vs. 19.7 ± 17.92) (p< 0.001),
and still signiﬁcantly higher in the CHC patients compared
to the control group (19.7 ± 17.92 vs. 2.79 ± 1.26)
(p< 0.001) (Table 1). Serum CLU (ng/ml) level showed a sig-
niﬁcant increase in the HCC group compared to the control
group (151.96 ± 32.74 vs. 111.40 ± 27.46) (p< 0.001) and
to the CHC group (151.96 ± 32.74 vs. 89.12 ± 31.62)
(p< 0.001), while a signiﬁcant decrease in serum CLU level
was found in the CHC group compared to the control group
(89.12 ± 31.62 vs. 111.40 ± 27.46) (p= 0.019) (Table 1)
(Fig. 1).
There was no signiﬁcant statistical difference in serum CLU
among the different Child-Pugh classes in either the CHC or
Table 1 Comparison between the studied groups according to serum levels of alpha fetoprotein (AFP) and clusterin (CLU).
Variable Control group G1 (n= 20) CHC group G2 (n= 27) HCC group G3 (n= 44)
AFP (ng/ml)
Range 1.4–5.3 2.4–63.4 2.3–41865
Mean ± SD 2.79 ± 1.26 19.7 ± 17.92 7243 ± 11613.6
Median 2.35 13.1 1200
Z1(p) 5.090
* (<0.001) 6.084* (<0.001)
Z2(p) 5.362
* (<0.001)
CLU (ng/ml)
Range 59–164.5 31.5–148.5 89.9–208.7
Mean ± SD 111.4 ± 27.46 89.12 ± 31.62 151.96 ± 32.74
Median 110.45 91.3 161.8
Z1(p) 2.337
*(p= 0.019) 4.179* (<0.001)
Z2(p) 5.901
* (<0.001)
G: group, CHC: chronic hepatitis-C virus infection related cirrhosis, HCC: hepatocellular carcinoma, AFP: alpha fetoprotein, CLU: clusterin.
Z1: Z for Mann–Whitney test between controls and other groups.
Z2: Z for Mann–Whitney test between CHC and HCC groups.
* Statistically signiﬁcant at p 6 0.005.
Figure 1 Boxplot of serum clusterin (CLU) in the studied groups. Box plot representing serum clusterin values in the studied groups:
Control, CHC: chronic hepatitis-C virus infection-related cirrhosis, HCC: hepatocellular carcinoma. The box indicates the 25th and 75th
percentile of the data and the middle line indicates the median.
230 R.A. Ramadan et al.HCC groups (Table 2). Also no signiﬁcant correlation was
found between serum CLU and Child-Pugh score (r= 0.09,
p= 0.458).
Moreover, when sorting HCC patients into those with
extrahepatic spread of HCC and those without, there was no
signiﬁcant increase in the level of both AFP (p= 0.710) and
CLU (p= 0.88). But when HCC patients were categorized
according to the Milan criteria, there was a signiﬁcant increase
in serum CLU in early stage HCC when compared to late stage
(172.84 ± 24.63 vs. 146.59 ± 32.67) (p= 0.035), but such an
increase was not present in serum AFP (p= 0.062) (Table 3).
When using the ROC curve for evaluating the diagnostic
performance of serum CLU in relation to serum AFP in diag-
nosing HCC, the area under the curve of AFP (0.912,
p< 0.001) was slightly bigger than that of CLU (0.874,
p< 0.001) (Fig. 2).Youden’s index was calculated to get the best cut off value
(COV). The optimal COV for serum CLU was 135 ng/ml and
this offered a diagnostic sensitivity of 70.5%, and a diagnostic
speciﬁcity of 90%. On the other hand, at a COV of 137 ng/ml,
serum AFP gave a diagnostic sensitivity of 77.3%, and a diag-
nostic speciﬁcity of 100%. The combined parallel approach
improved the diagnostic sensitivity to 95.5% and negative pre-
dictive value to 95.7% over the single use of serum AFP in
HCC cases, but decreased the speciﬁcity to reach 88% and
positive predictive value to 87.5% (Table 4).
4. Discussion
Hepatocellular carcinoma is a highly malignant and lethal
tumor, with an estimated 5-year survival rate of 5–9% from
the time of clinical diagnosis.1 It is considered a health burden
Table 2 Comparison of serum clusterin (ng/ml) in chronic hepatitis-C virus infection-related cirrhosis (CHC) and hepatocellular
carcinoma (HCC) groups according to Child-Pugh classes.
Child-Pugh classes A B C
CHC group (n= 27) N (%) 8 (29.6) 10 (37) 9 (33.3)
Range 42–148.5 31.5–145.3 50.7–142.9
Mean ± SD 98.65 ± 33.50 80.04 ± 33.31 90.83 ± 28.81
Median 95.8 75.4 89.7
Z1(p) 1.155 (p= 0.274) 0.577 (p= 0.606)
Z2(p) 0.858 (p= 0.4)
HCC group (n= 44) N (%) 13 (29.5) 14 (31.8) 17 (38.6)
Range 90.7–207.6 90.5–208.7 89.9–187.5
Mean ± SD 152.23 ± 37.31 154.95 ± 31.62 149.29 ± 31.76
Median 166.30 162.75 150.70
Z1(p) 0.291 (p= 0.793) 0.021 (p= 1)
Z2(p) 0.278 (p= 0.799)
G: group, CHC: chronic hepatitis-C virus infection related cirrhosis, HCC: hepatocellular carcinoma, n: number.
Z1: Z for Mann–Whitney test between Child-Pugh class A and other groups.
Z2: Z for Mann–Whitney test between Child-Pugh class B and Child-Pugh class C.
Table 3 Comparison of serum alpha fetoprotein (AFP) and
clusterin (CLU) in the hepatocellular carcinoma (HCC) group
according to different variables.
Staging according to
Milan criteria
Early stage Late stage
N (%) 9 (9.9) 35 (38.5)
AFP(ng/ml)
Range 2.3–41,865 2.4–36,300
Mean ± SD 4985.94 ± 13838.63 7823.49 ± 1127.57
Median 236 1375
Z (p) 1.862 (p= 0.062)
CLU (ng/ml)
Range 132.8–208.7 89.9–207.6
Mean ± SD 172.84 ± 24.63 146.59 ± 32.67
Median 175.9 146.2
Z (p) 2.109* (p= 0.035)
Extra-hepatic spread Absent Present
N (%) 34 (37.4) 10 (11)
AFP(ng/ml)
Range 2.3–41,865 5.4–31,704
Mean ± SD 7320 ± 11830.69 6981.25 ± 11450.10
Median 1223 656.05
Z (p) 0.392 (p= 0.710)
CLU (ng/ml)
Range 89.9–208.7 111.9–184.9
Mean ± SD 152 ± 34.91 151.82 ± 25.53
Median 161.8 156.25
Z (p) 0.168 (p= 0.88)
n: number.
Z: Z for Mann–Whitney test between the two subgroups.
* Statistically signiﬁcant at p 6 0.005.
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rently available diagnostic tools, HCC is frequently not diag-
nosed until it has reached an advanced stage when the
remaining therapeutic modalities are less effective, leaving this
disease with unfavorable prognosis.6 Therefore, ﬁnding newmarkers for screening and diagnosing HCC at an early stage
is highly recommended.
Clusterin (CLU) is a highly conserved glycoprotein with a
wide tissue distribution. Many physiological processes have
been attributed to CLU such as cell adhesion, tissue remodel-
ing, and immune system regulation.10
In the present study, serum CLU was measured by the
ELISA technique in a cohort of Egyptian patients (healthy
controls, HCV related liver cirrhosis, and HCC cases on top
of HCV related liver cirrhosis). We found a signiﬁcant decrease
in serum CLU level in the HCV related cirrhosis patients when
compared to the control group. Also, CLU level was higher in
Child class A patients compared to Child class C patients, as
summarized in Table 2. The difference, however, was statisti-
cally non-signiﬁcant. This may point to a possible protective
role of CLU against liver cell ﬁbrogenesis which ultimately
ends in cirrhosis. Such an assumption was similarly postulated
in renal ﬁbrosis by Jung et al, who suggested that up regulation
of clusterin during renal injury, in a mouse model, has a pro-
tective response against the development of renal ﬁbrosis.23
Likewise, Hogasen et al. and Wang et al. reported a decrease
in serum CLU in alcoholic liver cirrhosis and hepatitis B viral
liver cirrhosis, respectively.24,25
Clusterin was suggested to be either a pro-apoptotic or a
pro-survival factor, rendering it an attractive biomarker for
cancer studies as a diagnostic or prognostic or even surpris-
ingly a therapeutic tool.26,27 We found higher serum CLU in
the HCC group than both control and HCV related liver cir-
rhosis, denoting its role in carcinogenesis. Such an increase
was similarly reported in HCC in serum level as well as tissue
level by previous studies. The former was done by Nafee et al.28
who reported the signiﬁcant rise of serum CLU in viral related
HCC patients, and the latter was done by Kang et al with the
use of a tissue microarray method which revealed CLU over-
expression immunohistochemically in surgically resected
HCCs.12 Furthermore, the increase of CLU level was demon-
strated in other tumors; such as bladder cancer,29 colorectal
adenocarcinomas,30 and prostate cancer.31 Our ﬁnding leads
to hypothesize that CLU secretion occurs from tumor cells
Figure 2 Receiver operating curves (ROCs) comparing clusterin and alpha fetoprotein in diagnosing hepatocellular carcinoma. Receiver
operator curves (ROCs) comparing clusterin (CLU) and alpha fetoprotein (AFP) in patients with hepatocellular carcinoma (HCC) (G3)
vs. those with and without HCC (G1 and G2). The solid line (-) denotes AFP and the dotted line (—) denotes CLUS. The curves show the
optimal cutoff value for clusterin to be135 mg/mL and for AFP to be 136 ng/mL. Diagonal segments are produced by ties.
Table 4 Predictive performance of serum alpha fetoprotein
(AFP) and clusterin (CLU) as biomarkers for the detection of
hepatocellular carcinoma (HCC).
Statistical parameter AFP CLU
Cut oﬀ value (ng/ml) >137 >135
Sensitivity (%) 77.3 70.5
Speciﬁcity (%) 100 90
Positive predictive value (%) 100 86.1
Negative predictive value (%) 83.3 77.6
Youden’s index 0.7727 0.6045
Area under the receiver operator curve 0.912 0.874
p Value <0.001 <0.001
95% conﬁdence interval 0.85–0.975 0.804–0.943
232 R.A. Ramadan et al.in HCC and is reﬂected in its serum level. This is further sup-
ported by the fact that clusterin exists as both an intracellular
truncated form and an extracellular heterodimeric secreted gly-
coprotein, making clusterin the only known chaperone protein
to be secreted.32
A handful of studies tackled the issue of the diagnostic per-
formance of biomarkers in HCC. In the present study, serum
AFP with a cutoff level of 137 ng/ml outperformed serum
CLU with a cutoff level of 135 ng/ml in diagnostic sensitivity
(77.3% vs. 70.5%), speciﬁcity (100% vs. 90%), and positive
and negative predictive values (100% vs. 86.1% and 83.3%
vs. 77.6%, respectively). Moreover, the use of a combined par-
allel approach improved the diagnostic sensitivity (95.5%) and
negative predictive value (95.7%) over the single use of AFPbut decreased the speciﬁcity to reach 88% and positive predic-
tive value to be 87.5%, thus improving the sensitivity at the
expense of the speciﬁcity. On the contrary, Wang et al.,25 dem-
onstrated that serum CLU with a cutoff level of 50 ug/ml out-
performed serum AFP with a cutoff level of 15 ng/ml in
diagnostic sensitivity (91% vs. 67%), speciﬁcity (83% vs.
76%), positive and negative predictive values (93% vs. 88%
and 77% vs. 47% respectively). It is worth mentioning that
such a low cutoff level of AFP (15 ng/ml) is somehow not
applicable in countries with a high prevalence of hepatic dis-
eases especially HCV as in our country. The sensitivity and
speciﬁcity of the diagnostic biomarker are strongly dependent
on the cutoff value above which it is considered positive, and
such a cutoff value is affected by the criteria of the studied
sample (demographic, clinical, biochemical and statistical) as
well as implicated methodological assays, thus explaining the
wide variation in diagnostic performance of biomarkers in
different studies due to different sample criteria.
The relation of CLU to HCC progression was also variable
in different reports. In vitro study using HCC cell lines by Lau
et al.33 demonstrated that overexpression of CLU increased
cell migration and formation of metastatic tumor nodules,
but Wang et al.25 and Nafaa et al.28 found no signiﬁcant differ-
ence of CLU serum levels between different tumor sizes. In our
study we did not ﬁnd a signiﬁcant increase in serum CLU in
HCCs with extrahepatic spread when compared to HCC with-
out extrahepatic spread. Interestingly, our study revealed a sig-
niﬁcant increase in serum CLU level in early stage HCC when
compared to late stage HCC, such an increase was not found
in serum AFP. Although this subgroup of early stage HCC
CLU as a marker in the diagnosis of hepatocellular carcinoma 233comprised only 9 cases, this can be attributed to rarity of such
patients due to delayed diagnosis of HCC. We cannot deny the
possibility of a random effect due to the small size of this sub-
group rendering it difﬁcult for establishing reliable statistical
results that could be applied in clinical use. Therefore, we rec-
ommend investigating CLU level on a larger cohort to ascer-
tain such an association. But a possible explanation may be
that the CLU increase in late stages is directed to the nuclear
form rather than the secreted form. Moreover, the complex
nature of CLU and its multiple isoforms not only in tissues34
but also in serum should be considered. Pucci et al.35 explained
the diversity of CLU function in colorectal carcinoma by a
shift in the pattern of its isoform production. Also Rodrı´-
guez-Pin˜eiro et al.34 pointed to the importance of measuring
CLU isoforms over that of total serum level, when they dem-
onstrated the increase of some isoforms and the decrease or
absence of others in colorectal carcinoma.
Finally, we can conclude that serum AFP did better than
serum CLU in all aspects of diagnostic performance for diag-
nosing HCC, but still the combined parallel approach
improved the sensitivity which is required in screening high
risk populations such as CHC patients. But still, further
research of larger study populations and with various liver
functions status, will be required to examine whether serum
CLU is associated with speciﬁc liver disease etiologies.Conﬂict of interest
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